ii) Blockage of the STAT3 activation using pharmacological or molecular biology approaches totally abrogated miR-762 upregulation in IL-6-challenged NSCLC cells (Fig. 2f-h). The gene discussed is IL6; the disease is non-small cell lung carcinoma.